DiaMedica Therapeutics Inc. SEC filings DMAC
DiaMedica Therapeutics Inc. has 427 filings in SEC EDGAR's recent list, going back to May 16, 2007. Its latest annual report, Form ARS, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 10, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 22, 2025 | — |
| CORRESP | Letter to the SEC | Aug 20, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2025 | — |
| EFFECT | Filing | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 6, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2025 | — |
| D | Filing | Jul 25, 2025 | — |
| EFFECT | Filing | Jul 18, 2024 | — |
| CORRESP | Letter to the SEC | Jul 16, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2024 | — |
| D | Filing | Jul 2, 2024 | — |
| EFFECT | Filing | Apr 9, 2024 | — |
| CORRESP | Letter to the SEC | Apr 4, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2024 | — |
| EFFECT | Filing | Jul 7, 2023 | — |
| CORRESP | Letter to the SEC | Jul 5, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2023 | — |
| D | Filing | Jun 27, 2023 | — |
| D | Filing | Apr 18, 2023 | — |
| CT ORDER | Filing | Dec 22, 2021 | — |
| EFFECT | Filing | Oct 14, 2021 | — |
| CORRESP | Letter to the SEC | Oct 12, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2021 | — |
| D | Filing | Oct 6, 2021 | — |
| EFFECT | Filing | May 4, 2021 | — |
| CORRESP | Letter to the SEC | May 3, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2021 | — |
| EFFECT | Filing | Jan 9, 2020 | — |
| CORRESP | Letter to the SEC | Jan 7, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2020 | — |
| 8-A12B/A | Form 8-a12b/a | Jun 4, 2019 | — |
| CT ORDER | Filing | Dec 7, 2018 | — |
| EFFECT | Filing | Dec 6, 2018 | — |
| CERT | Filing | Dec 6, 2018 | — |
| CORRESP | Letter to the SEC | Dec 4, 2018 | — |
| CORRESP | Letter to the SEC | Dec 4, 2018 | — |
| 8-A12B | Form 8-a12b | Dec 3, 2018 | — |
| CORRESP | Letter to the SEC | Nov 28, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 27, 2018 | — |
| CORRESP | Letter to the SEC | Nov 19, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 2, 2018 | — |
| DRS | Filing | Nov 1, 2018 | — |
| DRSLTR | Filing | Nov 1, 2018 | — |
| DRS/A | Filing | Oct 19, 2018 | — |
| DRSLTR | Filing | Oct 18, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2018 | — |
| DRSLTR | Filing | Sep 17, 2018 | — |
| DRS/A | Filing | Sep 17, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2018 | — |
| DRS | Filing | Aug 27, 2018 | — |
| D | Filing | Apr 17, 2018 | — |
| RW | Filing | Apr 3, 2018 | — |
| 20FR12B/A | Form 20fr12b/a | Mar 11, 2014 | — |
| 20FR12B | Form 20fr12b | Jan 30, 2014 | — |
| REGDEX | Auto-generated paper document | May 16, 2007 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMAC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Minneapolis, MN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1401040
- Former names
- DiaMedica Inc. (until Mar 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.